Pediatric Kidney Transplant Recipient Registration Worksheet

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI® application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI® application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Name: SSN: HIC: Transplant Date and Time: State of Permanent Residence:* Permanent Zip:* Provider Information Recipient Center: Surgeon Name:*	
HIC: Transplant Date and Time: State of Permanent Residence: * Permanent Zip: * Provider Information Recipient Center: Surgeon Name: *	
State of Permanent Residence: * Permanent Zip: * Provider Information Recipient Center: Surgeon Name: *	
State of Permanent Residence: * Permanent Zip: * Provider Information Recipient Center: Surgeon Name: *	
Provider Information Recipient Center: Surgeon Name:*	
Provider Information Recipient Center: Surgeon Name:*	
Recipient Center: Surgeon Name:*	
Recipient Center: Surgeon Name:*	
Surgeon Name: *	
NPI#:*	
Donor Information	
UNOS Donor ID #:	
Recovering OPO:	
Donor Type:	
· · · · · · ·	
Patient Status	
Primary Diagnosis: *	
Specify:	
Date: Last Seen, Retransplanted or Death*	
Patient Status: * LIVING	
ODEAD	
RETRANSPLANTED	
Primary Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Specify.	
Transplant Hospitalization:	
Date of Admission to Tx Center:*	
Date of Discharge from Tx Center:	
Clinical Information : PRETRANSPLANT Functional Status: *	
i uncuonai Status: *	
Cognitive Development: * Definite Cognitive delay/impairment	
Probable Cognitive delay/impairment	
Questionable Cognitive delay/impairmen	.
	•
No Cognitive delay/impairment	
Not Assessed	
Copyright © 2023 United Network for Organ Sharing. All rights reserved. OPTN	use only 091423

Probable Motor delay/impairment Questionable Motor delay/impairment No Motor delay/impairment Not Assessed Academic Progress:* Within One Grade Level of Peers Delayed Grade Level	
No Motor delay/impairment Not Assessed Academic Progress:* Within One Grade Level of Peers	
Academic Progress:* Within One Grade Level of Peers	
Academic Progress: *	
-	
Dolayed Grade Lovel	
Delayet Grade Level	
Special Education	
Not Applicable, too young for school/ High School graduate or GED	
Status Unknown	
Academic Activity Level: *	
Reduced academic load	
Unable to participate in academics due to disease or condition	
Unable to participate regularly in academics due to dialysis	
Not Applicable, too young for school/ High School graduate or GED	
Status Unknown	
Source of Payment: Primary: *	
Specify:	
Height Measurement Date:	
Height: * ft. in. cm ST=	
Weight Measurement Date:	
Weight: ★	
BMI: kg/m ²	
Previous Transplants:	
Previous Transplant Organ Previous Transplant Date Previous Transplant Graft Fail Date	
The three most recent transplants are listed here. Please contact the UNet Help Desk to confirm more than three previous transplants by calling 800-978-4334 emailing unethelpdesk@unos.org.	or by
Pretransplant Dialysis: * YES NO UNK	
YES NO UNK	
If Yes, Date of Most Recent Initiation of Chronic Maintenance	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis:	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: * mg/dl ST=	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: * mg/dl ST=	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: * mg/dl ST = Viral Detection:	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: * mg/dl ST = Viral Detection: HIV Serostatus: * Positive	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: * mg/dl ST = Viral Detection: HIV Serostatus: * Positive Negative	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: * mg/dl ST = Viral Detection: HIV Serostatus: * Positive Negative Not Done	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: * Wiral Detection: HIV Serostatus: * Positive Negative Not Done UNK/Cannot Disclose	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: * Wiral Detection: HIV Serostatus: * Positive Negative Not Done UNK/Cannot Disclose CMV Status * Positive	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: * Wiral Detection: HIV Serostatus:* Positive Negative Not Done UNK/Cannot Disclose CMV Status* Positive Negative Negative Negative Negative Negative	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: * Wiral Detection: HIV Serostatus: * Positive Negative Not Done UNK/Cannot Disclose CMV Status * Positive Negative Not Done	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: * Wiral Detection: HIV Serostatus: * Positive Negative Not Done UNK/Cannot Disclose CMV Status * Positive Negative Negative Not Done UNK/Cannot Disclose	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: * Wiral Detection: HIV Serostatus: * Positive Negative Not Done UNK/Cannot Disclose CMV Status * Positive Negative Negative Not Done UNK/Cannot Disclose Not Done UNK/Cannot Disclose Not Done UNK/Cannot Disclose	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: * mg/dl ST = Viral Detection: HIV Serostatus: * Positive Negative Not Done UNK/Cannot Disclose CMV Status * Positive Negative Negative Not Done UNK/Cannot Disclose HBV Surface Antibody Total * Positive Negative Negative Not Done	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: ** Magative Not Done UNK/ Cannot Disclose Not Done UNK/ Cannot Disclose Not Done UNK/ Cannot Disclose Not Done Not	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: ** Magative Not Done UNK/ Cannot Disclose Not Done UNK/ Cannot Disclose Not Done UNK/ Cannot Disclose Not Done Not	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis: Serum Creatinine at Time of Tx: ** Magative Not Done UNK/ Cannot Disclose Not Done UNK/ Cannot Disclose Not Done UNK/ Cannot Disclose Not Done Not	

HBV Core Antibody: ∗	Positive
	Negative
	Not Done
	OUNK/Cannot Disclose
HBV Surface Antigen: ★	Positive
	Negative
	Not Done
	OUNK/Cannot Disclose
HCV Serostatus: ∗	Positive
	Negative
	Not Done
	OUNK/Cannot Disclose
EBV Serostatus: *	Positive
	Negative
	Not Done
	OUNK/Cannot Disclose
Vaccination Status:	
Did the recipient receive Hepatitis B vaccines prior to transplant?: $\pmb{\ast}$	OYES ONO OUNK
Reason not vaccinated:	○Immunity
	Medical precaution
	OTime constraints
	Patient objection
	Product out of stock
	Other, specify
Specify:	
NAT Results:	
HIV NAT: *	Positive
	Negative
	Not Done
	OUNK/Cannot Disclose
HBV NAT: ∗	Positive
	Negative
	Not Done
	OUNK/Cannot Disclose
HCV NAT: ∗	Positive
	Negative
	Not Done
	OUNK/Cannot Disclose
Previous Pregnancies:	YES
	ONO
	ONOT APPLICABLE: < 10 years old
Malignancies between listing and transplant: *	○YES ○NO
This question is NOT applicable for patients receiving living dor	nor transplants who were never on the waiting list.

Copyright © 2023 United Network for Organ Sharing. All rights reserved. OPTN use only. 091423

If yes, specify typ	e:	☐Skin Melanoma		
		Skin Non-Melanoma		
		□CNS Tumor		
		Genitourinary		
		□Breast		
		☐ Thyroid		
		☐Tongue/Throat/Larynx		
		Lung		
		Leukemia/Lymphoma		
		Liver		
		Other, specify		
Specify:				
эреспу.				
Bone Disease:				
Fracture in the pa	ast year (or since last follow-up):∗	OYES ONO OUNK		
Specify Location	and number of fractures: *	☐ Spine-compression fracture:	# of fractures:	
		☐ Extremity:	# of fractures:	
		Other:	# of fractures:	
AVN (avascular n	ecrosic): W	YES ONO OUNK		
AVIV (dvasculai III	CCI 0313). A	TES OND OUNK		
Clinical Inform	nation: TRANSPLANT PROCE	DUDE		_
Multiple Organ Rec		DOKE		
Were extra vessels	used in the transplant procedure:			
Procedure Type:				
Kidney Preservation	on Information:			
Total Cold ischemi- pumped, include p	a Time Right KI(OR EN-BLOC): (if ump time):	hrs	ST=	
Total Cold ischemic pump time):	a Time Left KI (if pumped, include	hrs	ST=	
Kidney(s) received	on:*	OIce		
		Pump		
		On/A		
Received on i	re:	Stayed on ice		
		Put on pump		
Received on p	bump:	Stayed on pump		
		Put on ice		
If put on pu	mp or stayed on pump:			
p p	inp or stayed on pump.			
	dney Final resistance at transplant:		ST=	
Right Ki			ST=	
Right Kio	dney Final resistance at transplant:			
Right Kid Right Kid Left Kidr	dney Final resistance at transplant:		ST=	
Right Kid Right Kid Left Kidi Left Kidi	dney Final resistance at transplant: dney Final flow rate at transplant: ney Final resistance at transplant:		ST=	
Right Kid Right Kid Left Kidr	dney Final resistance at transplant: dney Final flow rate at transplant: ney Final resistance at transplant:		ST=	
Right Kid Right Kid Left Kidi Left Kidi Organ Check-in Information: Left Kidney Check-In Date	dney Final resistance at transplant: dney Final flow rate at transplant: ney Final resistance at transplant:	Military time Time Zone:	ST=	
Right Kid Right Kid Left Kidn Left Kidn Organ Check-in Information: Left Kidney Check-In Date and Time:	dney Final resistance at transplant: dney Final flow rate at transplant: ney Final resistance at transplant: ney Final flow rate at transplant: Date:	·	ST=	
Right Kid Right Kid Left Kidi Left Kidi Organ Check-in Information: Left Kidney Check-In Date	dney Final resistance at transplant: dney Final flow rate at transplant: ney Final resistance at transplant: ney Final flow rate at transplant:	Military time Time Zone: Military time Time Zone:	ST = ST =	

Frauth is included for the respont, and the death was a result of some other factor underted to guilt failure, select Functioning. Leasumed Maintenance Dialysis: VES NO Date of Graft Failure: Primary Cause of Graft Failure: HYPPERACUTE REJECTION CACHTE REJECTION PRIMARY NON-FUNCTION (GRAFT NEVER FUNCTIONED POST-TRANSPLANT) GRAFT THROMBOSIS INFECTION SURGICAL COMPLICATIONS URGOLOGICAL COMPLICATIONS RECURRENT DISEASE OTHER SPECIFY CAUSE Specify: Speci	0.000	
Date Marterance Dialysis Resumed: Date Marterance Dialysis Resumed: Primary Cause of Graft Failure: Primary Cause of Graft Failur	Graft Status: *	○Functioning ○Failed
Date of Graft Failure: Primary Cause of Graft Failure: HYPERACUTE REJECTION ACUTE REJECTION PRIMARY NON-FUNCTION (GRAFT NEVER FUNCTIONED POST-TRANSPLANT) GRAFT THROMBOSIS INFECTION SURGICAL COMPLICATIONS URGOLOGICAL COMPLICATIONS RECURRENT DISEASE OTHER SPECIFY CAUSE Specify: floor Recent Serum Creatinine Prior to Discharge: * Patient Need Dialysis within First Week: * VES NO Ure, at least one episode treated with anti-rejection agent transplant and discharge: * Polic patient have any acute rejection episodes between transplant and discharge: * No Surgical Complex of the service of	If death is indicated for the recipient, and the death was a result o Resumed Maintenance Dialysis:	
Primary Cause of Graft Fallure: HYPERACUTE REJECTION	Date Maintenance Dialysis Resumed:	
ACUTE RESECTION PRIMARY NON-FUNCTION (GRAFT NEVER FUNCTIONED POST-TRANSPLANT) GRAFT THROMBOSIS INFECTION SURGICAL COMPLICATIONS URCLOGRICAL COMPLICATIONS RECURRENT DISEASE OTHER SPECIFY CAUSE	Date of Graft Failure:	
PRIMARY NON-FUNCTION (GRAFT NEVER FUNCTIONED POST-TRANSPLANT) GRAFT THROMBOSIS DIVECTION SURGICAL COMPLICATIONS OROLOGICAL COMPLICATIONS RECURRENT DISEASE OTHER SPECIFY CAUSE Specify: Most Recent Serum Creatinine Prior to Discharge: * mg/dl ST = * * * * * * * * * * * * * * * * * *	Primary Cause of Graft Failure:	CHYPERACUTE REJECTION
GRAFT THROMBOSIS INFECTION SURGICAL COMPLICATIONS URGODICAL COMPLICATIONS RECURRENT DISEASE OTHER SPECIFY CAUSE Specify: Most Recent Serum Creatinine Prior to Discharge: # YES NO Did patient have any acute rejection episodes between transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant and discharge: # Yes NO Did patient have any acute rejection episodes between transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant are discharge: # Yes, none treated with additional anti-rejection agent transplant are manufactured to the properties of th		CACUTE REJECTION
Surgical complications URGOGICAL COMPLICATIONS RECURRENT DISEASE OTHER SPECIFY CAUSE OTHER SPECIFY CAUSE Specify: Specify: Most Record Serum Creatinine Prior to Discharge: # Yes No Old patient have any acute rejection episodes between transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant and discharge: # Yes, none treated with additional anti-rejection agent transplant and trans		PRIMARY NON-FUNCTION (GRAFT NEVER FUNCTIONED POST-TRANSPLANT)
SURGICAL COMPLICATIONS UROLOGICAL COMPLICATIONS RECURRENT DISEASE OTHER SPECIFY CAUSE OTHER SPECIFY CAUSE Specify: Foot Recent Serum Creatinine Prior to Discharge: # mg/d ST = mg/d ST = mg/d ST = mg/d ST = mg/d		GRAFT THROMBOSIS
UROLOGICAL COMPLICATIONS RECURRENT DISEASE OTHER SPECIFY CAUSE Specify: mg/dl ST =		OINFECTION
RECURRENT DISEASE OTHER SPECIFY CAUSE OTHER SPECIFY CAUSE Floor Recent Serum Creatinine Prior to Discharge: #		SURGICAL COMPLICATIONS
Specify:		OUROLOGICAL COMPLICATIONS
Asset Recent Serum Creatinine Prior to Discharge: * mg/dl ST = relation Need Dialysis within First Week: * YES NO Did patient have any acute rejection episodes between transplant and discharge: * Yes, at least one episode treated with anti-rejection agent transplant and discharge: * Yes, none treated with additional anti-rejection agent Yes, none treated with additional anti-rejection Yes Yes, none treated Yes, and the yes Yes, none treated Yes, and the yes Yes, none treated Yes, none treated Yes, and the yes Yes, none treated Yes, none		CRECURRENT DISEASE
No Indicate Need Dialysis within First Week: * Ves No Did patient have any acute rejection episodes between transplant and discharge: * Ves, an least one episode treated with anti-rejection agent transplant and discharge: * Ves, none treated with additional anti-rejection agent Ves, none treated with additional anti-rejection agent No s growth homone therapy used between listing and Ves No UNK Immunosuppressive Information ver any medications given currently for maintenance or mir-rejection. * Immunosuppressive Medications frew Immunosuppressive Medications frew Immunosuppressive medications frew Immunosuppressive medications or each of the immunosuppressive medications frew Immunosuppressive medications or each of the immunosuppressive medications frew Immunosuppressive medications frew Immunosuppressive medications or each of the immunosuppressive medications or each of the immunosuppressive medications frew Immunosuppressive medications or each of the immunosuppressive medication or each of the immunosuppressive medica		OTHER SPECIFY CAUSE
No Indicate Need Dialysis within First Week: * Ves No Did patient have any acute rejection episodes between transplant and discharge: * Ves, an least one episode treated with anti-rejection agent transplant and discharge: * Ves, none treated with additional anti-rejection agent Ves, none treated with additional anti-rejection agent No s growth homone therapy used between listing and Ves No UNK Immunosuppressive Information ver any medications given currently for maintenance or mir-rejection. * Immunosuppressive Medications frew Immunosuppressive Medications frew Immunosuppressive medications frew Immunosuppressive medications or each of the immunosuppressive medications frew Immunosuppressive medications or each of the immunosuppressive medications frew Immunosuppressive medications frew Immunosuppressive medications or each of the immunosuppressive medications or each of the immunosuppressive medications frew Immunosuppressive medications or each of the immunosuppressive medication or each of the immunosuppressive medica	Specific	
Did patient have any acute rejection episodes between transplant and discharge: # Yes, at least one episode treated with anti-rejection agent Yes, at least one episode treated with anti-rejection agent Yes, none treated with additional anti-rejection agent Yes, none treated with additional anti-rejection agent No UNK Immunosuppressive Information The any medications given currently for maintenance or mit-rejection: # Yes No UNK Immunosuppressive Medications Per any medications given currently for maintenance or mit-rejection: # Yes No UNK Immunosuppressive Medications Few Immunosuppressive medications letted, select Ind (Induction), Maint (Maintenance) or AR (Anti-rejection) to indicate all medications that were rescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(e) blank moduction (and) immunosuppressive medications letted, select Ind (Induction), Maint (Maintenance) or AR (Anti-rejection) to indicate all medications that were rescribed for the required medicate and indicates ano	. ,	maldl ST
Did patient have any acute rejection episodes between transplant and discharge: * Ves, at least one episode treated with anti-rejection agent Ves, none treated with additional anti-rejection agent No s growth hormone therapy used between listing and ransplant: * Immunosuppressive Information we any medications given currently for maintenance or Wes No UNK Immunosuppressive Medications Wes No Infinitions of Immunosuppressive Medications Perintitions Perintit		
Yes, none treated with additional anti-rejection agent No OUNK Immunosuppressive Information Ive any medications given currently for maintenance or YES NO Immunosuppressive Medications Immunosuppressive medications given before, during or after transplant with the intention to maintain them [ggg-tem] (was present the one problem) two discharged in the space provided. For example, if Simulect was given in the propertive was discharged in the space provided. Immunosuppressive medications given before, during or after transplant with the intention to maintain them [ggg-tem] (was present them to the properties of the purpose of treating an acute rejection episode during the initial and transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example: methylpredin	ratient Need Dialysis within First Week: *	○YES ○NO
Yes, none treated with additional anti-rejection agent No as growth hormone therapy used between listing and Yes No Unk Immunosuppressive Information The any medications given currently for maintenance or Wes No Intregection: * Immunosuppressive Medications Definitions Of Immunosuppressive Medications Perfinitions Of Immunosuppressive Medications Perfinitions Of Immunosuppressive medications listed, select Ind (Induction), Maint (Maintenance) or AR (Anti-rejection) to indicate all medications that were rescribed for the immunosuppressive medications listed, select Ind (Induction), Maint (Maintenance) or AR (Anti-rejection) to indicate all medications that were rescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank anduction (Ind) immunosuppressive miditations given for a short finite period for rejection the first 3 days after transplant, it will map be used long-term for immunosuppressive maintenance rescribed for the purpose of preventing acute rejection regions of the first 3 days after transplant, it will map be used long-term for immunosuppressive maintenance of the second object on acute freities of an archer finite period for rejection therapy and vould be recorded as anti-rejection heapy if used for first purpose of preventing acute rejection and anti-rejection floors, for anti-ordinal anti-ordinal period for rejection therapy and vould be recorded as anti-rejection floor, for first office of another finite minorusoppressive medications given before, during a safet restanglant period for rejection (example medications) and anti-rejection floors, for first office or for induction or for induction or for induction and anti-rejection floors, or for induction and anti-rejection floors, or for induction or f		Yes, at least one episode treated with anti-rejection agent
s growth hormone therapy used between listing and ransplant: * Immunosuppressive Information we any medications given currently for maintenance or mit-rejection: * Immunosuppressive Medications fiew Immunosuppressive Medications Perinitions Of Immunosuppressive Medications or each of the immunosuppressive medications listed, select Ind (Induction), Maint (Maintenance) or AR (Anti-rejection) to indicate all medications that were rescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank induction (Ind) immunosuppressive medications given for a spot finite gening in the period period period in the period for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank induction (Ind) immunosuppressive medications given for a spot finite gening in the period for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank induction agents are usually polycholan, includes all maintenance. Another finite period for rejection therapy and would be recorded as anti-rejection therapy if used first research. For example, if Simulect was given in Induction gening in the second dose was given after the patient was discharged. Admitted that number of days the days was actually administered in the space provided. For example, if Simulect was given in the total number of days will mumosuppression before, during or after transplant with the intention to maintain them [ggg-term (example redictions, cyclosporine, torcilimus, mycophenolate mofetil, azathioprine, or Rapamune). This does not include any immunosuppression emidications given to treat dispection opisode during the initial mumosuppression but a finite period of uring a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection episode during		○No
Immunosuppressive Information we any medications given currently for maintenance or mit-rejection: * Immunosuppressive Medications fiew Immunosuppressive Medications fiew Immunosuppressive Medications or each of the immunosuppressive medications listed, select Ind (Induction), Maint (Maintenance) or AR (Anti-rejection) to indicate all medications that were rescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank induction (Ind) immunosuppressive medications given for a short finite period in the perioperative period for the purpose of preventing acute rejection hough the drugs may be continued after discharge for the first 30 days after transplant it, will may be used long-term for immunosuppressive minduction agents are usually polyclonal, monoclonal, or 1L2 receptor antibodies (example: methylpredinsolone, Campah, Thymogolobilin, or Simulect). Some of thes may may include the transplant indicated, write the total number of days the drug was actually administered in the spece provided, for example, if Simulate was given in 2 doses a week part then the total number of days would be 2, even fif the second dose was given after the patient was discharged. ### Alientenance (Maint) includes all immunosuppressive medications given before, during or after transplant with the intention to maintain them long-term (example recipisone, or cylosponie, tarcollinus, mycophenolate moterial, azationspine, or Repamuno). This does not include any immunosuppressive medications given to treat under-rejection (aNR) immunosuppressive medications given before, during or after transplant with the intention to maintain them long-term (example recipisone, or for induction. **Maintenance** (Maintenance** (Maintenance** (Maintenance**) includes all immunosuppressive medications given to treat decisions, or for induction. **Maintenance** (Maintenance**) includes all immunosuppressive medications given to treat decisions,		○No
Immunosuppressive Information we any medications given currently for maintenance or mit-rejection: * Immunosuppressive Medications fiew Immunosuppressive Medications fiew Immunosuppressive Medications or each of the immunosuppressive medications listed, select Ind (Induction), Maint (Maintenance) or AR (Anti-rejection) to indicate all medications that were rescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank induction (Ind) immunosuppressive medications given for a short finite period in the perioperative period for the purpose of preventing acute rejection hough the drugs may be continued after discharge for the first 30 days after transplant it, will may be used long-term for immunosuppressive minduction agents are usually polyclonal, monoclonal, or 1L2 receptor antibodies (example: methylpredinsolone, Campah, Thymogolobilin, or Simulect). Some of thes may may include the transplant indicated, write the total number of days the drug was actually administered in the spece provided, for example, if Simulate was given in 2 doses a week part then the total number of days would be 2, even fif the second dose was given after the patient was discharged. ### Alientenance (Maint) includes all immunosuppressive medications given before, during or after transplant with the intention to maintain them long-term (example recipisone, or cylosponie, tarcollinus, mycophenolate moterial, azationspine, or Repamuno). This does not include any immunosuppressive medications given to treat under-rejection (aNR) immunosuppressive medications given before, during or after transplant with the intention to maintain them long-term (example recipisone, or for induction. **Maintenance** (Maintenance** (Maintenance** (Maintenance**) includes all immunosuppressive medications given to treat decisions, or for induction. **Maintenance** (Maintenance**) includes all immunosuppressive medications given to treat decisions,	Is growth hormone therapy used between listing and	VES NO CHNIK
Immunosuppressive Medications // Community in the immunosuppressive Medications // Communosuppressive Medications given for a short finite, period in the perioperative period for the purpose of preventing acute rejection hough the drugs may be continued after discharge for the first 30 days after transplant, it will not be used long-term for minomunosuppressive medications given before days and transplant, it will not be used for enther first reason, for reach induction nedicated, write the total number of days with deep and would be recorded as anti-rejection therapy it used for this reason. For each induction nedicated, write the total number of days would be 2, even if the second dose was given after the patient was given for this reason. For each induction nedicated, write the total number of days would be 2, even if the second dose was given after the patient was discharged. // Adaintenance (Mainty) includes all immunosuppressive medications given before, during or after transplant with the intention to maintain them long-atem (example redisions, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, or Rapamune). This does not include any immunosuppressive medications given to treat the patient of days and the patient of days in the patient of days and the patient of da	rransplant: *	- CILS CHO CONK
Immunosuppressive Medications Pefinitions Of Immunosuppressive Medications Pefinitions Of Immunosuppressive Medications or each of the immunosuppressive medications listed, select Ind (Induction), Maint (Maintenance) or AR (Anti-rejection) to indicate all medications that were rescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank induction (Ind) immunosuppression includes all medications given for a short finite period in the perioperative period for the purpose of preventing acute rejection hough the drugs may be continued after discharge for the first 30 days after transplant, it will not be used for another finite period for rejection therapy and would be recorded as anti-rejection therapy if used for this reason. For each induction agents are usually polylonal, monoclonal, or IL-2 recorder as arculaple administered in the space provided. For example, if Simulect was given in 2 does a week part then the total number of days would be 2, even if the second dose was given after the patient was discharged. Maintenance (Maint) includes all immunosuppressive medications given before, during or after transplant with the intention to maintain them long-term (example redinsions, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, or Rapamune). This does not include any immunosuppressive medications given before, during or after transplant with the intention to maintain them long-term (example redinsions, or for induction. nutri-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode during the initial ost-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example: methylpredinisolone, or hymoglobulin). When switching maintenance drugs (example: from tacrolimus to cyclosporine; or from mycophenolate mofetil to azathioprine) because of rejectio	Immunosuppressive Information	0
Perfinitions Of Immunosuppressive Medications or each of the immunosuppressive Medications or each of the immunosuppressive medications listed, select Ind (Induction), Maint (Maintenance) or AR (Anti-rejection) to indicate all medications that were rescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank induction (Ind) immunosuppression includes all medications given for a short finite period in the perioperative period for the purpose of preventing acute rejection hough the drugs may be continued after discharge for the first 30 days after transplant, it will not be used for another finite period for rejection therapy and would be recorded as anti-rejection therapy if used for this reason. For each induction redictation indicated, write the total number of days the drug was actually administered in the space provided. For example, if Simulect was given in 2 doses a week part then the total number of days would be 2, even if the second dose was given after the patient was discharged. **Anintenance (Maint)** includes all immunosuppressive medications given before, during or after transplant with the intention to maintain them long-term (example redisione, cyclosporine, tarorlimus, mycophenolate mofetil, azathioprine, or Rapamune). This does not include any immunosuppressive medications given before, during or after transplant with the intention to maintain them long-term (example redisions, expection), as specific follow-up period, usually up to 30 days after the diagnosis of acute rejection episode during the initial ost-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example: methylpredisiolone, or hymoglobulin). When switching maintenance drugs (example: from tarcrilimus to cyclosporine; or from mycophenolate mofeitl to azathioprine) because of rejection, for all information of the medication in the space provided. Do not lis	anti-rejection: *	
Pefinitions Of Immunosuppressive Medications or each of the immunosuppressive medications listed, select Ind (Induction), Maint (Maintenance) or AR (Anti-rejection) to indicate all medications that were rescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank induction (Ind) immunosuppression includes all medications given for a short finite period in the perioperative period for the purpose of preventing acute rejection hough the drugs may be continued after discharge for the first 30 days after transplant, it will not be used long-term for immunosuppressive maintenance. Induction agents are usually polyclonal, monoclonal, or IL-2 receptor antibodies (example: methylprednislond) campably, induced and induction agents are usually polyclonal, monoclonal, or IL-2 receptor antibodies (example: methylprednislond) campably, induced was maintenance. Induction nedication indicated, write the total number of days the drug was actually administered in the space provided. For example, if Simulect was given in 2 doses a week part then the total number of days would be 2, even if the second dose was given after the patient was discharged. Maintenance (Maint) includes all immunosuppressive medications given before, during or after transplant with the intention to maintain them logog-term (example rednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, or Rapamune). This does not include any immunosuppressive medications given to treat ejection episodes, or for induction. Mitti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode during the initial ost-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example: methylprednisolone, or hymoglobulin). When switching maintenance drugs (example: from tacrolimus to cyclosporine; or from mycophenolate		
re each of the immunosuppressive medications listed, select Ind (Induction), Maint (Maintenance) or AR (Anti-rejection) to indicate all medications that were rescribed for the recipient during the initial transplant hospitalization period, and for what reason. If a medication was not given, leave the associated box(es) blank induction (Ind) immunosuppression includes all medications given for a short finite period in the perioperative period for the purpose of preventing acute rejection hough the drugs may be continued after discharge for the first 30 days after transplant, it will not be used long-term for immunosuppressive maintenance. Induction agents are usually polyclonal, monoclonal, or IL-2 receptor antibodies (example: methylprednisolone, Campath, Thymoglobulin, or Simulect). Some of thes rugs might be used for another finite period for rejection therapy and would be recorded as anti-rejection therapy if used for this reason. For each induction redictation indicated, write the total number of days the drug was actually administered in the space provided. For example, if simulect was given in 2 doses a week part then the total number of days moved the second dose was given after the patient was discharged. Alaintenance (Maint) inductions all immunosuppressive medications given before, during or after transplant with the intention to maintain them long-term (example redinsone, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, or Rapamune). This does not include any immunosuppressive medications given to treat ejection episodes, or for induction. Inti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode during the initial ost-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example: methylprednisolone, or hymoglobulin). When switching maintenance drugs (example: from tacrolimus to cyclosporine; or from reponencial to the propose of the purp		
nduction (Ind) immunosuppression includes all medications given for a <u>short finite period</u> in the perioperative period for the purpose of preventing acute rejection hough the drugs may be continued after discharge for the first 30 days after transplant, it <u>will not</u> be used long-term for immunosuppressive maintenance. Induction agents are usually polyclonal, monoclonal, or IL-2 receptor antibodies (example: methylprednisolone, Campath, Thymoglobulin, or Simulect). Some of thes rugs might be used for another finite period for rejection therapy and used for this reason. For each induction nedication indicated, write the <u>total number of days the drug was actually administered</u> in the space provided. For example, if Simulect was given in 2 doses a week part then the total number of days would be 2, even if the second dose was given after the patient was discharged. **Anintenance (Maint)* includes all immunosuppressive medications given before, during or after transplant with the intention to maintain them <u>long-term</u> (example rednisone, cyclosporine, tarcolimus, mycophenolate mofetil, azathioprine, or Rapamune). This does not include any immunosuppressive medications given to treat ejection ejectose, or for induction. **Inti-rejection (AR)* immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode during the initial ost-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example: methylprednisolone, or his production. When switching maintenance drugs (example: from tacrolimus to cyclosporine, or from prophenolate meteril to azathioprine) because of rejection, he drugs <u>should not</u> be listed under AR immunosuppression, but <u>should</u> be listed under maintenance immunosuppression. **Drugs used for induction, acute rejection, or maintenance Ind. Days ST Maint AR Maint AR Maint AR Maint AR Maint Maint Maint Maint Maint Maint Maint Maint Maint M	/iew Immunosuppressive Medications	
iost-transplant period or during a specific follow-up period, usually up to 30 days after the diagnosis of acute rejection (example: methylprednisolone, or hymoglobulin). When switching maintenance drugs (example: from tacrolimus to cyclosporine; or from mycophenolate mofetil to azathioprine) because of rejection, he drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression. In a immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other mmunosuppressive Medication field, and enter the full name of the medication in the space provided. Do not list non-immunosuppressive medications. Drug used for induction, acute rejection, or maintenance Ind. Days ST Maint AF steroids (prednisone, methylprednisolone, Solumedrol, Medrol) Drugs used for induction or acute rejection Ind. Days ST Maint AF steroids (prednisone, methylprednisolone, Solumedrol, Medrol) Campath (alemtuzumab)	Immunosuppressive Medications View Immunosuppressive Medications Definitions Of Immunosuppressive Medications	
f an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other munosuppressive Medication field, and enter the full name of the medication in the space provided. Do not list non-immunosuppressive medications. Drug used for induction, acute rejection, or maintenance	Definitions Of Immunosuppressive Medications or each of the immunosuppressive medications listed, select Indirescribed for the recipient during the initial transplant hospitalization includes all medications given though the drugs may be continued after discharge for the first 30 duction agents are usually polyclonal, monoclonal, or IL-2 recepturugs might be used for another finite period for rejection therapy nedication indicated, write the total number of days the drug was part then the total number of days would be 2, even if the second faintenance (Maint) includes all immunosuppressive medication rednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azath	on period, and for what reason. If a medication was not given, leave the associated box(es) be not a short finite period in the perioperative period for the purpose of preventing acute reject days after transplant, it will not be used long-term for immunosuppressive maintenance. or antibodies (example: methylprednisolone, Campath, Thymoglobulin, or Simulect). Some of the and would be recorded as anti-rejection therapy if used for this reason. For each induction actually administered in the space provided. For example, if Simulect was given in 2 doses a windose was given after the patient was discharged. In signer before, during or after transplant with the intention to maintain them long-term (example).
Ind. Days ST Maint AF iteroids (prednisone, methylprednisolone, Solumedrol, Medrol) Drugs used for induction or acute rejection Ind. Days ST Maint AF atgam Campath (alemtuzumab)	Definitions Of Immunosuppressive Medications or each of the immunosuppressive medications listed, select Indorescribed for the recipient during the initial transplant hospitalizate induction (Ind) immunosuppression includes all medications give though the drugs may be continued after discharge for the first 30 induction agents are usually polyclonal, monoclonal, or IL-2 recept larges might be used for another finite period for rejection therapy nedication indicated, write the total number of days the drug was upart then the total number of days would be 2, even if the second Maintenance (Maint) includes all immunosuppressive medication rednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azathejection episodes, or for induction. Inti-rejection (AR) immunosuppression includes all immunosup toost-transplant period or during a specific follow-up period, usually Thymoglobulin). When switching maintenance drugs (example: fro	on period, and for what reason. If a medication was not given, leave the associated box(es) be not a short finite period in the perioperative period for the purpose of preventing acute reject days after transplant, it will not be used long-term for immunosuppressive maintenance. or antibodies (example: methylprednisolone, Campath, Thymoglobulin, or Simulect). Some of the and would be recorded as anti-rejection therapy if used for this reason. For each induction actually administered in the space provided. For example, if Simulect was given in 2 doses a wardose was given after the patient was discharged. In given before, during or after transplant with the intention to maintain them long-term (examiliary) for Rapamune). This does not include any immunosuppressive medications given to transplant or resessive medications given to the purpose of treating an acute rejection episode during the injug to 30 days after the diagnosis of acute rejection (example: methylprednisolone, or macrolimus to cyclosporine; or from mycophenolate mofetil to azathioprine) because of rejection to the purpose of treating an acute rejection episode during the injug to 30 days after the diagnosis of acute rejection (example: methylprednisolone, or macrolimus to cyclosporine; or from mycophenolate mofetil to azathioprine) because of rejection the purpose of treating and the province of the purpose of the
teroids (prednisone, methylprednisolone, Solumedrol, Medrol) Drugs used for induction or acute rejection	Teem Immunosuppressive Medications Definitions Of Immunosuppressive Medications or each of the immunosuppressive medications listed, select Indirescribed for the recipient during the initial transplant hospitalizate induction (Ind) immunosuppression includes all medications given though the drugs may be continued after discharge for the first 3 diduction agents are usually polyclonal, monoclonal, or IL-2 recept rugs might be used for another finite period for rejection therapy hedication indicated, write the total number of days the drug was part then the total number of days would be 2, even if the second laintenance (Maint) includes all immunosuppressive medication rednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azathejection episodes, or for induction. Inti-rejection (AR) immunosuppression includes all immunosup ost-transplant period or during a specific follow-up period, usually hymoglobulin). When switching maintenance drugs (example: from the drugs should not be listed under AR immunosuppression, but set an immunosuppression believed in the second set and immunosuppression that set is being the second second set and immunosuppression that set is being the second seco	on period, and for what reason. If a medication was not given, leave the associated box(es) be not a short finite period in the perioperative period for the purpose of preventing acute reject days after transplant, it will not be used long-term for immunosuppressive maintenance. or antibodies (example: methylprednisolone, Campath, Thymoglobulin, or Simulect). Some of the and would be recorded as anti-rejection therapy if used for this reason. For each induction actually administered in the space provided. For example, if Simulect was given in 2 doses a windose was given after the patient was discharged. It is given before, during or after transplant with the intention to maintain them long-term (example), or Rapamune). This does not include any immunosuppressive medications given to tree pressive medications given for the purpose of treating an acute rejection episode during the initiant poly to 30 days after the diagnosis of acute rejection (example: methylprednisolone, or matacrolimus to cyclosporine; or from mycophenolate mofetil to azathioprine) because of rejectionally be listed under maintenance immunosuppression. In administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other
Drugs used for induction or acute rejection Ind. Days ST Maint AF atgam ampath (alemtuzumab)	Definitions Of Immunosuppressive Medications or each of the immunosuppressive medications listed, select Induces of the recipient during the initial transplant hospitalizate induction (Ind) immunosuppression includes all medications given hough the drugs may be continued after discharge for the first 30 anduction agents are usually polyclonal, monoclonal, or IL-2 recept larges might be used for another finite period for rejection therapy nedication indicated, write the total number of days the drug was part then the total number of days would be 2, even if the second Maintenance (Maint) includes all immunosuppressive medication rednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azathejection episodes, or for induction. Inti-rejection (AR) immunosuppression includes all immunosupprost-transplant period or during a specific follow-up period, usually hymoglobulin). When switching maintenance drugs (example: from the drugs should not be listed under AR immunosuppression, but set an immunosuppressive medication other than those listed is beir mmunosuppressive Medication field, and enter the full name of the	on period, and for what reason. If a medication was not given, leave the associated box(es) be not a short finite period in the perioperative period for the purpose of preventing acute rejected as after transplant, it will not be used long-term for immunosuppressive maintenance. For antibodies (example: methylprednisolone, Campath, Thymoglobulin, or Simulect). Some of the and would be recorded as anti-rejection therapy if used for this reason. For each induction actually administered in the space provided. For example, if Simulect was given in 2 doses a was given after the patient was discharged. It is given before, during or after transplant with the intention to maintain them long-term (example), or Rapamune). This does not include any immunosuppressive medications given to tree pressive medications given for the purpose of treating an acute rejection episode during the initiation of the purpose of treating and acute rejection episode during the initiation of the purpose of treating and the properties of the purpose of treating and the purpose of treating and the purpose of treating and the properties of the purpose of treating and the purpose of
tgam Ind. Days ST Maint AF	refinitions Of Immunosuppressive Medications or each of the immunosuppressive medications listed, select Indrescribed for the recipient during the initial transplant hospitalizate induction (Ind) immunosuppression includes all medications given by though the drugs may be continued after discharge for the first 30 raduction agents are usually polyclonal, monoclonal, or IL-2 recept rugs might be used for another finite period for rejection therapy redication indicated, write the total number of days the drug was part then the total number of days would be 2, even if the second laintenance (Maint) includes all immunosuppressive medication rednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azath rejection episodes, or for induction. Inti-rejection (AR) immunosuppression includes all immunosuppost-transplant period or during a specific follow-up period, usually hymoglobulin). When switching maintenance drugs (example: from the drugs should not be listed under AR immunosuppression, but so immunosuppressive medication other than those listed is being minunosuppressive Medication field, and enter the full name of the minunosuppressive Medication field, and enter the full name of the second and the second and the full name of the minunosuppressive Medication field, and enter the full name of the second and the full recommendation in the full name of the minunosuppressive medication field, and enter the full name of the second and the full recommendation in the full recommendation	on period, and for what reason. If a medication was not given, leave the associated box(es) be not a short finite period in the perioperative period for the purpose of preventing acute rejected as after transplant, it will not be used long-term for immunosuppressive maintenance. or antibodies (example: methylprednisolone, Campath, Thymoglobulin, or Simulect). Some of the and would be recorded as anti-rejection therapy if used for this reason. For each induction actually administered in the space provided. For example, if Simulect was given in 2 doses a wardose was given after the patient was discharged. In given before, during or after transplant with the intention to maintain them long-term (example), or Rapamune). This does not include any immunosuppressive medications given to tree pressive medications given for the purpose of treating an acute rejection episode during the initial up to 30 days after the diagnosis of acute rejection (example: methylprednisolone, or materolimus to cyclosporine; or from mycophenolate mofetil to azathioprine) because of rejectioneld be listed under maintenance immunosuppression. g administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other emedication in the space provided. Do not list non-immunosuppressive medications. maintenance Ind. Days ST Maint
ergam C C C C C C C C C C C C C C C C C C C	reach of the immunosuppressive Medications or each of the immunosuppressive medications listed, select Indrescribed for the recipient during the initial transplant hospitalizate aduction (Ind) immunosuppression includes all medications given ough the drugs may be continued after discharge for the first 30 duction agents are usually polyclonal, monoclonal, or IL-2 recept ugs might be used for another finite period for rejection therapy edication indicated, write the total number of days the drug was art then the total number of days would be 2, even if the second adintenance (Maint) includes all immunosuppressive medication edinisone, cyclosporine, tacrolimus, mycophenolate mofetil, azatrigection (AR) immunosuppression includes all immunosupp sst-transplant period or during a specific follow-up period, usually hymoglobulin). When switching maintenance drugs (example: froe drugs should not be listed under AR immunosuppression, but ge an immunosuppressive medication other than those listed is bein nmunosuppressive Medication field, and enter the full name of the prug used for induction, acute rejection, or	on period, and for what reason. If a medication was not given, leave the associated box(es) be not a short finite period in the perioperative period for the purpose of preventing acute rejected as after transplant, it will not be used long-term for immunosuppressive maintenance. or antibodies (example: methylprednisolone, Campath, Thymoglobulin, or Simulect). Some of the and would be recorded as anti-rejection therapy if used for this reason. For each induction actually administered in the space provided. For example, if Simulect was given in 2 doses a wardose was given after the patient was discharged. In given before, during or after transplant with the intention to maintain them long-term (example), or Rapamune). This does not include any immunosuppressive medications given to tree pressive medications given for the purpose of treating an acute rejection episode during the initial up to 30 days after the diagnosis of acute rejection (example: methylprednisolone, or materolimus to cyclosporine; or from mycophenolate mofetil to azathioprine) because of rejectioneld be listed under maintenance immunosuppression. g administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other emedication in the space provided. Do not list non-immunosuppressive medications. maintenance Ind. Days ST Maint
ampath (alemtuzumab)	refinitions Of Immunosuppressive Medications or each of the immunosuppressive medications listed, select Indrescribed for the recipient during the initial transplant hospitalizate induction (Ind) immunosuppression includes all medications given bough the drugs may be continued after discharge for the first 30 roduction agents are usually polyclonal, monoclonal, or IL-2 recept rugs might be used for another finite period for rejection therapy redication indicated, write the total number of days the drug was part then the total number of days would be 2, even if the second laintenance (Maint) includes all immunosuppressive medication rednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azath rejection (AR) immunosuppression includes all immunosuppost-transplant period or during a specific follow-up period, usually hymoglobulin). When switching maintenance drugs (example: frome drugs should not be listed under AR immunosuppression, but a fan immunosuppressive medication other than those listed is bein munosuppressive Medication field, and enter the full name of the Drug used for induction, acute rejection, or teroids (prednisone, methylprednisolone, Solumedrol, Medrol)	on period, and for what reason. If a medication was not given, leave the associated box(es) be not a short finite period in the perioperative period for the purpose of preventing acute rejected as after transplant, it will not be used long-term for immunosuppressive maintenance. or antibodies (example: methylprednisolone, Campath, Thymoglobulin, or Simulect). Some of the and would be recorded as anti-rejection therapy if used for this reason. For each induction actually administered in the space provided. For example, if Simulect was given in 2 doses a wardose was given after the patient was discharged. In given before, during or after transplant with the intention to maintain them long-term (example), or Rapamune). This does not include any immunosuppressive medications given to tree pressive medications given for the purpose of treating an acute rejection episode during the initial up to 30 days after the diagnosis of acute rejection (example: methylprednisolone, or materolimus to cyclosporine; or from mycophenolate mofetil to azathioprine) because of rejectioneld be listed under maintenance immunosuppression. g administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other emedication in the space provided. Do not list non-immunosuppressive medications. maintenance Ind. Days ST Maint
	refinitions Of Immunosuppressive Medications or each of the immunosuppressive medications listed, select Indrescribed for the recipient during the initial transplant hospitalizate induction (Ind) immunosuppression includes all medications given bough the drugs may be continued after discharge for the first 30 roduction agents are usually polyclonal, monoclonal, or IL-2 recept rugs might be used for another finite period for rejection therapy redication indicated, write the total number of days the drug was part then the total number of days would be 2, even if the second laintenance (Maint) includes all immunosuppressive medication rednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azath rejection (AR) immunosuppression includes all immunosuppost-transplant period or during a specific follow-up period, usually hymoglobulin). When switching maintenance drugs (example: frome drugs should not be listed under AR immunosuppression, but a fan immunosuppressive medication other than those listed is bein munosuppressive Medication field, and enter the full name of the Drug used for induction, acute rejection, or teroids (prednisone, methylprednisolone, Solumedrol, Medrol)	on period, and for what reason. If a medication was not given, leave the associated box(es) be in for a short finite period in the perioperative period for the purpose of preventing acute reject days after transplant, it will not be used long-term for immunosuppressive maintenance. Or antibodies (example: methylprednisolone, Campath, Thymoglobulin, or Simulect). Some of the and would be recorded as anti-rejection therapy if used for this reason. For each induction actually administered in the space provided. For example, if Simulect was given in 2 doses a was given after the patient was discharged. In significant of the patient was discharged. In significant of the purpose of treating an acute rejection episode during the initial up to 30 days after the diagnosis of acute rejection (example: methylprednisolone, or metacrolimus to cyclosporine; or from mycophenolate mofetil to azathioprine) because of rejectioneld be listed under maintenance immunosuppression. In administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other emedication in the space provided. In Days ST Maint Ind. Days ST Maint Ind. Days ST Maint Ind. Days ST Maint
Vtoxan (cyclophosphamide)	Definitions Of Immunosuppressive Medications or each of the immunosuppressive medications listed, select Inducescribed for the recipient during the initial transplant hospitalizat nduction (Ind) immunosuppression includes all medications given though the drugs may be continued after discharge for the first 30 induction agents are usually polyclonal, monoclonal, or IL-2 recept larges might be used for another finite period for rejection therapy nedication indicated, write the total number of days the drug was part then the total number of days would be 2, even if the secondaintenance (Maint) includes all immunosuppressive medication rednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azatrejection episodes, or for induction. Inti-rejection (AR) immunosuppression includes all immunosupionst-transplant period or during a specific follow-up period, usually hymoglobulin). When switching maintenance drugs (example: from the drugs should not be listed under AR immunosuppression, but generally in the properties of the international properties of the drugs should not be listed under AR immunosuppression, but generally international properties of the drugs should not be listed under AR immunosuppression, but generally international properties of the drugs should not be listed under AR immunosuppression, but generally should not be listed under AR immunosuppression, but generally should not be listed under AR immunosuppression, but generally should not be listed under AR immunosuppression, but generally should not be listed under AR immunosuppression, but generally should not be listed under AR immunosuppression, but generally should not be listed under AR immunosuppression, but generally should not be listed under AR immunosuppression, but generally should not be listed under AR immunosuppression, but generally should not be listed under AR immunosuppression, but generally should not be listed under AR immunosuppression, but generally should not be laterally should not be laterally should not be laterally should	on period, and for what reason. If a medication was not given, leave the associated box(es) be in for a short finite period in the perioperative period for the purpose of preventing acute reject days after transplant, it will not be used long-term for immunosuppressive maintenance. Or antibodies (example: methylprednisolone, Campath, Thymoglobulin, or Simulect). Some of the and would be recorded as anti-rejection therapy if used for this reason. For each induction actually administered in the space provided. For example, if Simulect was given in 2 doses a was given after the patient was discharged. In significant of the patient was discharged. In significant of the purpose of treating an acute rejection episode during the initial up to 30 days after the diagnosis of acute rejection (example: methylprednisolone, or metacrolimus to cyclosporine; or from mycophenolate mofetil to azathioprine) because of rejectioneld be listed under maintenance immunosuppression. In administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other emedication in the space provided. In Days ST Maint Ind. Days ST Maint Ind. Days ST Maint Ind. Days ST Maint
	Definitions Of Immunosuppressive Medications For each of the immunosuppressive medications listed, select Induction for each of the recipient during the initial transplant hospitalizate induction (Ind) immunosuppression includes all medications giver though the drugs may be continued after discharge for the first 30 induction agents are usually polyclonal, monoclonal, or IL-2 recept larges might be used for another finite period for rejection therapy nedication indicated, write the total number of days the drug was upart then the total number of days would be 2, even if the second Maintenance (Maint) includes all immunosuppressive medication or discovered in the second Maintenance (Maint) includes all immunosuppression ejection episodes, or for induction. Anti-rejection (AR) immunosuppression includes all immunosupprost-transplant period or during a specific follow-up period, usually hymoglobulin). When switching maintenance drugs (example: from the drugs should not be listed under AR immunosuppression, but set an immunosuppressive medication other than those listed is bein mmunosuppressive Medication field, and enter the full name of the drugs should not be set and the full of the full name of the minimunosuppressive Medication field, and enter the full name of the set of the drugs should not be set of the full name of the minimunosuppressive Medication field, and enter the full name of the set of the full name of the full n	on period, and for what reason. If a medication was not given, leave the associated box(es) be in for a short finite period in the perioperative period for the purpose of preventing acute reject days after transplant, it will not be used long-term for immunosuppressive maintenance. Or antibodies (example: methylprednisolone, Campath, Thymoglobulin, or Simulect). Some of the and would be recorded as anti-rejection therapy if used for this reason. For each induction actually administered in the space provided. For example, if Simulect was given in 2 doses a was given after the patient was discharged. In significant of the patient was discharged. It is significant to maintain them long-term (example), or Rapamune). This does not include any immunosuppressive medications given to the purpose of treating an acute rejection episode during the initiation of the purpose of treating an acute rejection episode during the initiation of the purpose of treating and the provided provided and the provided provided be listed under maintenance immunosuppression. In administered (e.g., new monoclonal antibodies), select Ind, Maint, or AR next to Other the medication in the space provided. Do not list non-immunosuppressive medications. Ind. Days ST Maint Ind. Days ST Maint Ind. Days ST Maint

Methotrexate (Folex PFS, Mexate-AQ, Rheumatrex)					
Rituxan (rituximab)					
Simulect (basiliximab)					
Thymoglobulin					
Drugs primarily used for maintenance	Ind.	Days	ST	Maint	AR
Cyclosporine, select from the following:					
- Gengraf					
- Neoral					
- Sandimmune					
- Generic cyclosporine					
Imuran (azathioprine, AZA)					
Leflunomide (LFL)					
Mycophenolic acid, select from the following:					
- CellCept (MMF)					
- Generic MMF (generic CellCept)					
- Myfortic (mycophenolic acid)					
- Generic Myfortic (generic mycophenolic acid)					
mTOR inhibitors, select from the following:					
- Rapamune (sirolimus)					
- Generic sirolimus					
- Zortress (everolimus)					
Nulojix (belatacept)					
Tacrolimus, select from the following:					
- Astagraf XL (extended release tacrolimus)					
- Envarsus XR (tacrolimus XR)					
- Prograf (tacrolimus)					
- Generic tacrolimus (generic Prograf)					
Other drugs	Ind.	Days	ST	Maint	AR
Other immunosuppressive medication, specify:					
Other immunosuppressive medication, specify:					

Copyright © 2023 United Network for Organ Sharing. All rights reserved. Confidential - OPTN Use Only

UNOS Policies & Terms